Wall Street analysts forecast that Vericel Corp (NASDAQ:VCEL) will announce earnings per share of ($0.07) for the current quarter, according to Zacks. Two analysts have provided estimates for Vericel’s earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.07). Vericel posted earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 53.3%. The firm is expected to announce its next earnings results on Tuesday, May 14th.

On average, analysts expect that Vericel will report full-year earnings of $0.07 per share for the current financial year, with EPS estimates ranging from $0.02 to $0.10. For the next year, analysts anticipate that the business will report earnings of $0.27 per share, with EPS estimates ranging from $0.22 to $0.36. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Vericel.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.07. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. The firm had revenue of $31.34 million during the quarter, compared to analysts’ expectations of $28.69 million. During the same quarter in the previous year, the company posted $0.01 EPS. Vericel’s revenue was up 34.2% on a year-over-year basis.

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Vericel from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. BidaskClub cut shares of Vericel from a “buy” rating to a “hold” rating in a research report on Friday, March 15th. Needham & Company LLC cut shares of Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective for the company. in a research report on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Vericel in a research report on Tuesday, January 29th. They issued an “outperform” rating and a $23.00 price objective for the company. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Vericel currently has a consensus rating of “Buy” and an average target price of $19.58.

In other Vericel news, Director Steven C. Gilman sold 7,500 shares of Vericel stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $18.02, for a total transaction of $135,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Gerard J. Michel sold 10,000 shares of Vericel stock in a transaction on Monday, March 11th. The stock was sold at an average price of $20.02, for a total transaction of $200,200.00. Following the sale, the chief financial officer now directly owns 122,249 shares of the company’s stock, valued at approximately $2,447,424.98. The disclosure for this sale can be found here. Insiders have sold a total of 58,711 shares of company stock valued at $1,034,580 in the last ninety days. Company insiders own 4.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. United Services Automobile Association grew its holdings in Vericel by 5.6% during the 4th quarter. United Services Automobile Association now owns 267,464 shares of the biotechnology company’s stock worth $4,654,000 after acquiring an additional 14,160 shares during the period. BlackRock Inc. grew its holdings in shares of Vericel by 10.8% in the 3rd quarter. BlackRock Inc. now owns 2,865,843 shares of the biotechnology company’s stock valued at $40,551,000 after buying an additional 279,408 shares during the period. Meeder Asset Management Inc. grew its holdings in shares of Vericel by 28.7% in the 4th quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 1,284 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Vericel in the 3rd quarter valued at $4,725,000. Finally, Jane Street Group LLC acquired a new position in shares of Vericel in the 3rd quarter valued at $239,000. 83.40% of the stock is owned by hedge funds and other institutional investors.

VCEL stock traded up $0.01 during trading on Monday, hitting $18.19. The company had a trading volume of 844,000 shares, compared to its average volume of 684,726. Vericel has a 12 month low of $8.95 and a 12 month high of $21.00. The stock has a market capitalization of $796.41 million, a PE ratio of -129.93 and a beta of 3.04.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Further Reading: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.